Further studies indicated that treatment with neutralizing anti-CD44 antibodies reduced tumor burden on the peritoneal wall and diaphragm in a xenograft mouse model [65], suggesting that targeting CD44 is a promising approach for the reduction of peritoneal tumor. Here, CD44 is linked to neoplasm.